# A Robustness-Oriented Quantum–Classical Hybrid Machine Learning Pipeline for Breast Cancer Diagnosis

**Published:** 2026  
**PubMed:** https://pubmed.ncbi.nlm.nih.gov/42449777/  
**Full text:** https://pmc.ncbi.nlm.nih.gov/articles/PMC13360165/

## Why this is one of the most important papers here
Many QML papers report only accuracy on an internal split. This work explicitly asks what a more **clinically credible evaluation framework** should look like.

## Models / concepts
The study considers approaches including:
- Variational Quantum Classifiers (VQC)
- Quantum Support Vector Machines (QSVM)
- Strong classical models
- Hybrid quantum-classical evaluation

It emphasizes:
- external validation
- calibration
- explainability
- decision-curve analysis
- reproducibility

## Central conclusion
The authors do **not** claim raw quantum superiority. Their conclusion is that modern classical learners can already be near the performance ceiling on curated breast-cancer benchmarks, so the current value of QML research may lie in rigorous benchmarking and studying new representations rather than claiming higher accuracy.

## Excellent project blueprint
Your team could adopt this philosophy:
1. Pick a breast-cancer dataset.
2. Train classical baselines first.
3. Add QSVM/VQC.
4. Use cross-validation.
5. Test calibration.
6. Add explainability (for example SHAP on classical/hybrid components).
7. Test an external dataset if compatible.
8. Report failures and quantum resource costs.

## Evidence level / caution
**Methodologically strong benchmark evidence; explicitly not proof of clinical readiness.**
